Muscle cramps in liver cirrhosis: Pathophysiology, burden, and emerging therapeutic approaches

Table 1 Comparative critical appraisal of therapies for muscle cramps in cirrhosis

Treatment category	Proposed mechanism (in cirrhosis cramps)	Best available cirrhosis-specific evidence (design; n)	Effect signal (frequency/severity/duration)	Level of evidence1	Key limitations	Adverse events/cautions
Taurine	Membrane/ion-channel stabilization; may reduce peripheral nerve/muscle hyperexcitability in taurine-deficient cirrhosis	Double-blind randomized crossover trial (n = 30); multiple small open-label studies/case series (n = 9-12)	Generally, reduces cramp frequency and severity; response varies	Moderate	Small samples; heterogeneous populations; short follow-up; patient-reported outcomes	Usually well tolerated; occasional dyspepsia
L-carnitine	Improves mitochondrial fatty-acid transport/ATP availability; may improve muscle energetics and ammonia handling	Prospective treatment study (n = 42; 8 weeks)	High proportion report improvement; VAS cramp score decreases	Low	Non-randomized; placebo effect likely; short duration; limited objective endpoints	Typically, well tolerated; possible GI upset/odor; caution with severe renal impairment
Branched-chain amino acids	Restores amino-acid balance; supports muscle metabolism; may improve sarcopenia and albumin; may stabilize neuromuscular function	Multicenter randomized trial of timing regimens (n = 37; 3 months) + small prospective studies	Reduced frequency (notably nocturnal dosing) and improved patient-reported health/QoL	Low-moderate	Often compares regimens rather than placebo; nutritional co-interventions; adherence variability	Mostly mild GI symptoms (bloating/distention); rare pruritus
Muscle relaxant: Baclofen	Central GABA-B agonist; reduces motor neuron excitability	Randomized open-label placebo-controlled trial (n = 100; 3 months) + small case series	Large decreases in frequency, intensity and duration; rebound after washout described	Moderate	Open-label expectation bias; titration individualized; limited long-term data	Drowsiness/sedation, constipation, nausea; caution with encephalopathy risk and falls
Muscle relaxant: Methocarbamol/eperisone	Central antispasmodic effects; reduces spasm and perceived pain	Methocarbamol RCT (n = 100; 1 month); eperisone open-label (n = 21; 8 weeks)	Methocarbamol: Marked reduction in cramps and pain scores; eperisone: Complete/partial response in many	Moderate (methocarbamol); low (eperisone)	Short follow-up; limited replication; subjective endpoints; safety data limited in decompensated cirrhosis	Dry mouth, dizziness; sedation - caution with CNS depressants and fall risk
Albumin infusion (intravenous)	Improves effective arterial blood volume/renal-RAAS physiology; may reduce circulatory triggers	Randomized crossover vs placebo (n = 12; weekly infusions)	Reduced cramp frequency during infusion period; effect wanes after stopping	Low	Very small sample; intravenous therapy resource-intensive; optimal dose/schedule unclear	Cost/intravenous access burden; volume overload/pulmonary edema risk in susceptible patients
Zinc	Corrects hypozincemia; neuromuscular stabilization (uncertain)	Small uncontrolled study in hypozincemia patients (n = 12; 12 weeks)	Many report improvement/resolution	Very low	No control group; selection bias; unclear generalizability beyond deficiency states	Diarrhea; with prolonged/high dose - copper deficiency risk (monitor if long-term)
Vitamin E	Antioxidant; theoretical benefit via oxidative-stress pathways	Case series suggests benefit; randomized double-blind placebo-controlled crossover pilot (n = 9) negative	Conflicting; controlled data do not show consistent benefit	Very low	Small, underpowered studies; inconsistent designs; deficiency status not standardized	Generally tolerated; high-dose long-term vitamin E may increase bleeding risk - caution with coagulopathy/anticoagulation
Quinine/quinidine	Modulates excitability at motor endplate; prolongs refractory period	Cirrhosis RCT with quinidine (n = 31; 4 weeks); broader non-cirrhosis meta-analyses show modest benefit	May reduce frequency; duration effects inconsistent	Low (cirrhosis-specific)	Safety concerns outweigh benefit; limited cirrhosis-specific trials; not guideline-recommended	Serious risks: Immune thrombocytopenia/pancytopenia, TTP/HUS, QT prolongation/arrhythmias, hypoglycemia - generally avoid

¹Level of evidence is a pragmatic synthesis based on study design, sample size, risk of bias, and consistency (not a formal Grading of Recommendations, Assessment, Development and Evaluation assessment). GABA-B: γ-aminobutyric acid type B receptor; RAAS: Renin-angiotensin-aldosterone system; RCT: Randomized controlled trial; VAS: Visual Analogue Scale; QoL: Quality of life; GI: Gastrointestinal; CNS: Central nervous system; TTP: Thrombotic thrombocytopenic purpura; HUS: Hemolytic uremic syndrome; QT interval.

Table 2 Summary of therapeutic studies for muscle cramps in liver cirrhosis

Therapy	Study design	Sample size (n)	Duration	Key outcomes	Major limitations	Strength of evidence
Taurine	Randomized crossover + open-label studies	9-30	4-8 weeks	↓Cramp frequency, severity, and duration	Small samples; subjective outcomes; short follow-up	Moderate
L-carnitine	Prospective observational study	42	8 weeks	↓Cramp frequency; ↓VAS scores	Non-randomized; placebo effect possible	Low
BCAA	Randomized trial (timing regimens)	37	3 months	↓Cramp frequency; ↑QoL	No placebo control; nutritional confounding	Low-Moderate
Baclofen	Randomized open-label placebo-controlled	100	3 months	↓Frequency, severity, duration	Open-label; sedation risk	Moderate
Methocarbamol	Randomized controlled trial	100	1 month	Marked ↓cramps and pain scores	Short duration; limited replication	Moderate
Albumin (intravenous)	Randomized crossover	12	4 weeks	↓Cramp frequency during treatment	Very small sample; intravenous burden	Low
Zinc	Uncontrolled pilot study	12	12 weeks	Symptom improvement in majority	No control group; selection bias	Very low
Vitamin E	Case series + RCT crossover	9-23	4 weeks	Conflicting results	Underpowered; inconsistent design	Very low
Quinine/quinidine	RCT	31	4 weeks	↓Cramp frequency	Serious adverse effects	Low

BCAA: Branched-chain amino acids; RCT: Randomized controlled trial; VAS: Visual Analogue Scale; QoL: Quality of life.